<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01039233</url>
  </required_header>
  <id_info>
    <org_study_id>50013</org_study_id>
    <nct_id>NCT01039233</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized, Bioequivalence Study of Bicalutamide 50 mg Tablet and Casodex 50 mg Tablet Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kremers Urban Development Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Watson Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kremers Urban Development Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of bicalutamide&#xD;
      50 mg tablet (test) versus Casodex (reference), administered as 1 x 50 mg tablet under&#xD;
      fasting conditions&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration)</measure>
    <time_frame>144 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf area under the concentration-time curve from time zero to infinity)</measure>
    <time_frame>144 hour</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum observed concentration of drug substance in plasma)</measure>
    <time_frame>144 hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bioequivalency</condition>
  <arm_group>
    <arm_group_label>Bicalutamide 50 mg Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Casodex® 50 mg Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet</intervention_name>
    <arm_group_label>Bicalutamide 50 mg Tablet</arm_group_label>
    <arm_group_label>Casodex® 50 mg Tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, non-smoker, 18 years of age and older;&#xD;
&#xD;
          -  Capable of consent;&#xD;
&#xD;
          -  BMI≥19.0 and &lt;30.0 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks prior to the administration of the&#xD;
             study medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the Medical Sub-Investigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.&#xD;
&#xD;
          -  History of significant alcohol abuse or drug abuse within one year prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Regular use of alcohol within six months prior to the screening visit (more than&#xD;
             fourteen units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL&#xD;
             of 40% alcohol]).&#xD;
&#xD;
          -  Use of soft drugs (such as marijuana) within 3 months prior to the screening visit or&#xD;
             hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the&#xD;
             screening visit or positive urine drug screen at screening.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole;&#xD;
             examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides,&#xD;
             imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days&#xD;
             prior to administration of the study medication.&#xD;
&#xD;
          -  Use of an investigational drug or participation in an investigational study within 30&#xD;
             days prior to administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric, or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products (including natural food supplements, vitamins.&#xD;
             garlic as a supplement) within 7 days prior to administration of study medication,&#xD;
             except for topical products without systemic absorption.&#xD;
&#xD;
          -  Difficulty to swallow study medication.&#xD;
&#xD;
          -  Use of any tobacco products in the 6 months preceding drug administration.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             Medical Sub-Investigator, could contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  A depot injection or an implant of any drug within 3 months prior to administration of&#xD;
             study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or&#xD;
             loss of whole blood (excluding the volume of blood that will be drawn during the&#xD;
             screening procedures of this study) prior to administration of the study medication as&#xD;
             follows:&#xD;
&#xD;
               -  50 mL to 300 mL of whole blood within 30 days,&#xD;
&#xD;
               -  301 mL to 500 mL of whole blood within 45 days, or&#xD;
&#xD;
               -  more than 500 mL of whole blood within 56 days prior to drug administration.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>73 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SFBC Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SFBC Anapharm</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>December 23, 2009</study_first_submitted>
  <study_first_submitted_qc>December 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2009</study_first_posted>
  <last_update_submitted>December 23, 2009</last_update_submitted>
  <last_update_submitted_qc>December 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Richard Larouche, M.D., Medical Director</name_title>
    <organization>sfbc Anapharm</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 8, 2010</submitted>
    <returned>February 25, 2010</returned>
    <submitted>August 12, 2010</submitted>
    <returned>September 1, 2010</returned>
    <submitted>June 23, 2011</submitted>
    <returned>July 22, 2011</returned>
    <submitted>July 27, 2011</submitted>
    <returned>August 29, 2011</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

